Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. Gilead is dedicated to transforming and simplifying care for people with life-threatening illnesses around the world. We also recognize that it takes more than medicine to address challenges patients and communities face in accessing the best possible care, and we know that passion for scientific discovery alone — and that Gilead alone — cannot solve these challenges. Gilead applies the same values of partnership, integrity, and dedication to our work tackling the social and structural challenges that patients, healthcare providers and other partners must overcome to identify and elevate the best possible solutions.
In 2022, Funders Concerned about AIDS (FCAA) recognize Gilead as the top overall funder of HIV-relate philanthropy. Gilead is also recognized in the report as the number one funder in the U.S. and the number three funder internationally. Gilead continues to go where the need is greatest, continuously testing what works and investing in what makes the most impact. The Gilead Compass Initiative®, a 10-year, more than $100 million commitment represents sustained efforts to work with our partners through COMPASS Coordinating Centers, the Southern HIV Impact Fund, and direct donations to other organizations to combat the disproportionate impact of the HIV/AIDS epidemic in the South. Gilead has developed several global strategic giving initiatives to go beyond medicine and address social and structural determinants of health and was recently recognized as the number one U.S. company in charitable cash giving by the Chronicle of Philanthropy.